Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CLK1 | P49759 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790083 | 0.88 | OGA (0.52) | OGAMAPK10KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2878987 | 0.83 | MKNK1 (0.43) | HPGDLMNAALDH1A1KDM4ECYP1A2 | |
| SCHEMBL2883441 | 0.77 | OGA (0.53) | HPGDOGALMNAHTTSMN1; SMN2 | |
| SCHEMBL2883879 | 0.76 | MAOA (0.49) | HPGDTSHRLMNAHTTSMN1; SMN2 | |
| SCHEMBL2120263 | 0.76 | LTA4H (0.65) | ALDH1A1CLK4CYP1A2CYP3A4CYP2C19 | |
| Pyridine SCHEMBL3569017 | 0.74 | KCNH3 (0.44) | HPGDTSHRLMNAHTTSMN1; SMN2 | |
| Pyridine SCHEMBL3572978 | 0.74 | F2 (0.39) | LMNASMN1; SMN2CLK4CYP3A4CYP2C19 | |
| SCHEMBL2884302 | 0.73 | MAPK9 (0.44) | HPGDMAPK10ALDH1A1KDM4ECDK2 | |
| SCHEMBL11988197 | 0.72 | KDM4E (0.55) | TSHROGAALDH1A1KDM4ECLK4 | |
| SCHEMBL9681154 | 0.72 | HPGD (0.51) | HPGDTSHRLMNAHTTMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-7776854-B2 | Benzazole derivatives for the treatment of scleroderma | MERCK SERONO SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | disclosed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | disclosed |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | HPGD 2766/4885TSHR 2539/4885OGA 2071/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | HPGD 3719/4885TSHR 4615/4885OGA 3903/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | HPGD 1135/4885TSHR 3432/4885OGA 1441/4885 |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | SMAD3, SQOR, TNNI3 | HPGD 1085/4885TSHR 763/4885OGA 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.